Trial reportDocumenta ophthalmologica. Advances in ophthalmology2002
The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.
Trial report in Documenta ophthalmologica. Advances in ophthalmology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 44 citations in OpenAlex.
- Electroretinographic (ERG) responses in pediatric patients using vigabatrin.Documenta ophthalmologica. Advances in ophthalmology · 2012Article
- Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats.Molecular and cellular neurosciences · 2010Article
- Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2009Article
- Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.Documenta ophthalmologica. Advances in ophthalmology · 2008Article
- [Anticonvulsants in the treatment of anxiety--an alternative treatment option?].Der Nervenarzt · 2007Review
- Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.Documenta ophthalmologica. Advances in ophthalmology · 2006Article
- Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.Journal of psychiatry & neuroscience : JPN · 2005Review
- Reduced visual function associated with infantile spasms in children on vigabatrin therapy.Investigative ophthalmology & visual science · 2005Article
- Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.Ophthalmology · 2004Article
- The effect of GABA and the GABA-uptake-blocker NO-711 on the b-wave of the ERG and the responses of horizontal cells to light.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2004Article
- Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.Documenta ophthalmologica. Advances in ophthalmology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the visual electrophysiology and visual fields of patients taking vigabatrin to those of a control group of epileptics on other anti-epileptic drugs (AEDs).
methodsFourteen epileptics treated with vigabatrin and 10 control patients treated with other AEDs underwent ERG and EOG. Goldmann visual fields were performed and analysed using standard software to measure areas contained within I4e isopters.
resultsThe cone and rod b-waves of the ERG, the oscillatory potential amplitudes and Arden indices were reduced in vigabatrin-treated subjects and the oscillatory potentials delayed. The Arden indices were reduced due to an increased dark trough. The areas contained within the I4e isopter of vigabatrin treated subjects were reduced compared to the control group and these areas correlated well with oscillatory potential amplitudes and b-wave amplitudes in the vigabatrin group only.
conclusionsThe use of vigabatrin is associated with a reduction of the ERG cone b-wave amplitude and oscillatory potentials which correlates with visual field loss. The Arden ratio is reduced in subjects taking vigabatrin but may recover after cessation. However, visual loss may persist in the presence of a recovered EOG. These findings suggest further effects of the drug than those mediated by GABA receptors, and support the contention that the cause of the field loss may be at least in part due to retinal effects. Possible mechanisms are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.